What is the appropriate systematic assessment and initial management for a patient presenting with anxiety and depression?

Systematic Assessment and Initial Management of Anxiety and Depression

Begin with validated screening tools at the initial visit: use the PHQ-9 for depression and GAD-7 for anxiety, then immediately assess for safety concerns including suicidal ideation and risk of harm to self or others. 1

Screening Protocol

When to Screen:

• Initial visit/diagnosis
• At appropriate intervals during ongoing care
• With changes in clinical status
• During transitions in care
• As clinically indicated 1

Screening Tools:

• Depression: PHQ-9 (9-item self-report scale)

  • Score 0-4: minimal symptoms
  • Score 5-9: mild depression
  • Score 10-14: moderate depression
  • Score 15-19: moderately severe depression
  • Score ≥20: severe depression 1

• Anxiety: GAD-7 (7-item self-report scale)

  • Score 0-4: minimal anxiety
  • Score 5-9: mild anxiety
  • Score 10-14: moderate anxiety
  • Score 15-21: severe anxiety 1

Alternative validated tools include HADS (Hospital Anxiety and Depression Scale, cutoff ≥8 for caseness) or combined screening measures 1.

Immediate Safety Assessment

Before proceeding with any other evaluation, determine:

• Risk of harm to self or others
• Presence of suicidal ideation, intent, or plan
• Presence of psychosis, severe agitation, or confusion/delirium

If YES to any safety concern: Immediate referral for emergency psychiatric evaluation; facilitate safe environment with one-to-one observation; initiate harm-reduction interventions 1

If NO: Proceed with comprehensive assessment 1

Comprehensive Assessment

Medical Evaluation First:

• Rule out medical causes: uncontrolled pain, fatigue, thyroid dysfunction, electrolyte imbalances, infection
• Rule out substance-induced causes: medications (corticosteroids, interferon), alcohol, stimulants, withdrawal states
• Rule out delirium 1

Psychiatric Assessment Components:

1. Symptom Characterization

   • Specific anxiety symptoms: panic attacks, trembling, sweating, tachycardia, palpitations, excessive worry
   • Specific depressive symptoms: low mood, anhedonia, sleep disturbance, appetite changes, concentration difficulties, guilt, psychomotor changes
   • Duration and frequency of symptoms
   • Severity and functional impairment in home, work/school, and social domains 1

2. Risk Factors and History

   • Personal or family history of anxiety/depression
   • Prior psychiatric treatment and response
   • Comorbid psychiatric conditions (50-60% of patients with depression have comorbid anxiety) 1
   • Substance use or abuse history
   • Presence of chronic medical illnesses 1

3. Functional Impairment

   • Impact on daily activities, relationships, occupational/academic performance
   • Subjective distress level
   • Coping skills and social support availability 1

Critical Distinction for Anxiety: Generalized anxiety disorder presents with multiple excessive worries that may appear as "concerns" or "fears" disproportionate to actual risk (e.g., excessive fear of recurrence, worry about multiple unrelated areas beyond the presenting problem) 1, 2

Initial Management Algorithm

For Comorbid Anxiety and Depression:

Treat depression first when both conditions coexist 1

Stepped Care Model Based on Severity:

Minimal to Mild Symptoms (PHQ-9: 0-9, GAD-7: 0-9):

• Psychoeducation about the condition, symptoms, and natural course
• Supportive care by primary team
• Self-help resources and lifestyle interventions
• Monitor with reassessment 1

Moderate Symptoms (PHQ-9: 10-14, GAD-7: 10-14):

• Psychoeducation and supportive care
• First-line: Cognitive-behavioral therapy (CBT) or other evidence-based psychotherapy
• Consider pharmacotherapy if:
  • Patient preference
  • Limited access to psychotherapy
  • History of good response to medication
  • Presence of significant functional impairment 1, 3

Moderate-Severe to Severe Symptoms (PHQ-9: ≥15, GAD-7: ≥15):

• Confirm diagnosis with structured assessment (DSM-5 criteria) before initiating treatment
• Recommend combined treatment: Pharmacotherapy AND psychotherapy
• Referral to psychiatry/psychology for diagnostic confirmation and specialized treatment 1

Treatment Options

Pharmacotherapy:

First-Line Medications (no specific agent superior to another):

• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)

Selection Criteria:

• Adverse effect profile
• Drug-drug interactions with current medications
• Prior treatment response
• Patient preference
• Tolerability 1, 3

Critical Caveat: Avoid benzodiazepines for long-term use due to risk of dependence, cognitive impairment, and adverse effects. Use only time-limited if needed 1

Psychological Interventions:

First-Line: Cognitive-behavioral therapy (CBT)

• Other evidence-based options: psychoeducational therapy, exercise programs
• Should be delivered by appropriately trained individuals
• Use treatment manuals for empirically supported treatments
• Measure outcomes pre- and post-treatment 1

Follow-Up and Reassessment

Biweekly to monthly monitoring until symptom remission:

• Assess treatment adherence (patients with depression often lack motivation for follow-through)
• Monitor medication compliance and adverse effects
• Evaluate satisfaction with treatment
• Assess functional improvement 1

At 8 weeks:

• If poor symptom reduction despite good compliance: alter treatment course
  • Add psychological intervention to medication or vice versa
  • Change specific medication
  • Refer for individual therapy if group therapy ineffective
  • Consider psychiatric consultation 1

Referral Indications

Immediate psychiatric referral:

• Risk of harm to self/others
• Severe symptoms with marked functional impairment
• Psychosis, severe agitation, or delirium
• Diagnostic uncertainty
• Treatment-resistant cases 1, 2

Common Pitfall: Failing to reassess patients who don't follow through with referrals or treatment recommendations. Active outreach and barrier assessment are essential, particularly for depressed patients who may lack motivation to engage 1.